KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Non-Current Deffered Revenue (2016 - 2025)

Ionis Pharmaceuticals has reported Non-Current Deffered Revenue over the past 17 years, most recently at $92.0 million for Q4 2025.

  • Quarterly results put Non-Current Deffered Revenue at $92.0 million for Q4 2025, down 41.21% from a year ago — trailing twelve months through Dec 2025 was $92.0 million (down 41.21% YoY), and the annual figure for FY2025 was $92.0 million, down 41.21%.
  • Non-Current Deffered Revenue for Q4 2025 was $92.0 million at Ionis Pharmaceuticals, down from $107.9 million in the prior quarter.
  • Over the last five years, Non-Current Deffered Revenue for IONS hit a ceiling of $402.0 million in Q1 2021 and a floor of $92.0 million in Q4 2025.
  • Median Non-Current Deffered Revenue over the past 5 years was $251.8 million (2023), compared with a mean of $247.2 million.
  • Biggest five-year swings in Non-Current Deffered Revenue: dropped 14.08% in 2021 and later tumbled 41.21% in 2025.
  • Ionis Pharmaceuticals' Non-Current Deffered Revenue stood at $351.9 million in 2021, then fell by 18.22% to $287.8 million in 2022, then dropped by 16.19% to $241.2 million in 2023, then tumbled by 35.11% to $156.5 million in 2024, then crashed by 41.21% to $92.0 million in 2025.
  • The last three reported values for Non-Current Deffered Revenue were $92.0 million (Q4 2025), $107.9 million (Q3 2025), and $125.1 million (Q2 2025) per Business Quant data.